Presentation of Phase I clinical results from DT-9081, an EP4 receptor antagonist, and preclinical data on DT-7012, a Treg depleting anti-CCR8 antibody Preclinical findings highlight immuno-oncology breakthrough properties for its PAR2 biased negative allosteric modulator program Posters...
Hence then, the article about domain therapeutics to present data on its gpcr lead programs at aacr annual meeting 2025 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Domain Therapeutics to Present Data on its GPCR Lead Programs at AACR Annual Meeting 2025 )
Also on site :
- 1971 Variety Hour That Turned a Husband-and-Wife Singing Duo Into TV's Biggest Comedy Act Debuted 55 Years Ago Today
- Trump backs off from new strikes on Iran, claiming Mideast allies have outlines of an emerging deal to reopen the Strait of Hormuz
- Burnham pledges more cost of living support as chancellor says public being ‘taken for a ride’ on food and petrol prices